Results 21 to 30 of about 218,137 (295)

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis [PDF]

International Journal of Molecular Sciences, 2021
Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes.
Ioannis A. Vathiotis, Georgia Gomatou, Dimitrios J. Stravopodis, Nikolaos Syrigos   +3 more
openaire   +3 more sources

Immunohistochemical Expression of Programmed Death Ligand-1 and CD-8 in Glioblastoma [PDF]

QJM: An International Journal of Medicine, 2021
Background Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor in adults. It is characterized by its extremely poor prognosis despite the available treatment strategies. Immune evasion is described in Glioblastoma via the PD-L1/ PD-1 interaction.
Dina Mohamed El Samman, Manal Mohamed El Mahdy, Hala Sobhy Cousha, Zeinab Abd El Rahman Kamar, Khaled Abdel Karim Mohamed, Hoda Hassan Abou Gabal   +5 more
openaire   +3 more sources

Programmed death-ligand 1 expression in rectal cancer [PDF]

European Surgery, 2016
Colorectal cancer (CRC) is the fourth most common cause of death worldwide. Approximately 30 % of all CRC occurs in the rectum. Improvements in survival rates were achieved thanks to multimodal therapy, combining surgery and chemoradiation. Nevertheless, the prognosis of patients suffering from rectal cancer (RC) remains poor.
Jomrich, G., Silberhumer, G. R., Marian, B., Beer, A., Müllauer, L.   +4 more
openaire   +2 more sources

Programmed Cell Death Ligand 1 Expression in Osteosarcoma [PDF]

Cancer Immunology Research, 2014
Abstract Programmed cell death ligand 1 (PDL1, also known as B7H1) is a cell-surface protein that suppresses the cytotoxic CD8+ T-cell–mediated immune response. PDL1 expression and its clinical relevance in sarcomas are not well understood.
Jacson K, Shen, Gregory M, Cote, Edwin, Choy, Pei, Yang, David, Harmon, Joseph, Schwab, G Petur, Nielsen, Ivan, Chebib, Soldano, Ferrone, Xinhui, Wang, Yangyang, Wang, Henry, Mankin, Francis J, Hornicek, Zhenfeng, Duan   +13 more
openaire   +2 more sources

Clinicopathological features of thymoma with the expression of programmed death-ligand 1 [PDF]

Annals of Oncology, 2018
Programmed death ligand 1 (PD-L1) is reportedly expressed in various malignancies and is considered a prognostic factor. We attempted to reveal the usefulness of the PD-L1 expression as a prognostic factor in patients with thymoma.Eighty-one patients with thymoma who underwent surgical resection between 2004 and 2015 were retrospectively reviewed.
Shuhei, Hakiri, Takayuki, Fukui, Shunsuke, Mori, Koji, Kawaguchi, Shota, Nakamura, Naoki, Ozeki, Taketo, Kato, Masaki, Goto, Yasushi, Yatabe, Kohei, Yokoi   +9 more
openaire   +2 more sources

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer [PDF]

Korean Journal of Clinical Oncology, 2017
Purpose Programmed death-1 and its ligands (PD-L1 and PD-L2) can induce T-cell apoptosis in many solid tumors, although there is limited information regarding their roles in colorectal cancer.
Jee Hyun Ahn, Hyun Yong Lee, Dong Hyun Kang, Geum Jong Song, Tae Sung Ahn, Myoung Won Son, Moon Soo Lee, Moo-Jun Baek   +7 more
doaj   +1 more source

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

Frontiers in Immunology, 2017
Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis.
Christodoulos Filippis, Katharina Arens, Gaetan Aime Noubissi Nzeteu, Gabriele Reichmann, Zoe Waibler, Peter Crauwels, Ger van Zandbergen, Ger van Zandbergen   +7 more
doaj   +1 more source

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]

, 2012
A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin, Bak, Peter, Barnkob, Mike Stein, Chen, Jianzhu, Higham, Eileen M., Wittrup, Karl Dane   +5 more
core   +1 more source